Doctors began testing PSA levels in the 1980s to monitor diagnosed cancers. By the early 1990s, researchers promoted it for ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

The Decipher Prostate test is already widely used in the US to help identify localised prostate cancer more likely to spread. It becomes the first molecular test with clinical evidence from a ...

The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three different PSA tests to create one risk ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier ...

Effects of a deep learning network on imaging quality of low-b-value diffusion–weighted imaging and lesion detection in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence, Swedish ...